Viktor Jorgens, MD


October 22, 2012

This feature requires the newest version of Flash. You can download it here.

Hello. I am Viktor Jorgens, Executive Director of the European Association for the Study of Diabetes (EASD), and I welcome you today on the first day of our annual meeting in the city of Berlin. The Association's meeting this year is attended by more than 18,000 participants from more than 120 countries. It is the place where all researchers worldwide unite to discuss all new aspects of diabetes: basic research, treatment, and care.

We will have more than 1300 presentations at this annual meeting, and it is impossible to summarize all of these scientific results. Therefore, if you would like to see a presentation from the meeting and listen to the science, or if you want to see the posters, then please download our app (EASD 2012), which is absolutely free of charge. On this app, you can see all of the sessions just a couple of minutes after the session ends, and you can take a "virtual poster walk" in the poster discussion session.

This year's meeting is extremely interesting because there have never been so many new attempts to treat diabetes. We have a very large number of new agents that are able to lower blood glucose, and the possibilities of care for people with diabetes have never been so effective. All of these new drugs, which are on the market, are near to coming to the market, or are in early development, are discussed in specific sessions. We are looking as well at the basic research that tries to discover the pathogenesis of type 2 and type 1 diabetes, because the main objective of our Association is to one day have presentations by people who will later receive 2 Nobel Prizes for discovering why type 1 diabetes occurs and the pathogenesis of type 2 diabetes.

If you are able to attend our meeting, I hope that you benefit from our virtual conference tool, and your feedback on the Internet would be very welcome.

Thank you for listening.